Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 261 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: aflibercept (ziv-aflibercept) Clear all
Terminated Phase 2 Interventional Results available

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

NCT02387957
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Fovista®, bevacizumab, ranibizumab, aflibercept
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

NCT01972763
View directory record Official record
Conditions
Recalcitrant Wet Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 9, 2026, 12:42 AM EDT
Withdrawn Not applicable Interventional

Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy

NCT01941173
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
ziv-aflibercept, leucovorin calcium, irinotecan hydrochloride, fluorouracil
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
3
States / cities
Duarte, California • Lancaster, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

NCT00650923
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
Interventions
ziv-aflibercept, radiation therapy, temozolomide, pharmacological study, laboratory biomarker analysis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

NCT00284141
View directory record Official record
Conditions
Pulmonary Diseases, Neoplasms, Lung
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 1 Interventional

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

NCT00622414
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ziv-aflibercept
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Early Phase 1 Interventional

Photobiomodulation for the Treatment of Diabetic Macular Edema

NCT02457975
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
670nm PBM, intravitreous VEGF-inhibitors
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 9, 2026, 12:42 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)

NCT03577899
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
Biological
Lead sponsor
Chengdu Kanghong Biotech Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 9, 2026, 12:42 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

NCT07705555
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
MK-8748, Aflibercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Glendale, California • Sacramento, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

VEGF Trap in Treating Patients With Metastatic Breast Cancer

NCT00369655
View directory record Official record
Conditions
Metastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 9, 2026, 12:42 AM EDT
Completed No phase listed Observational

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

NCT05791695
View directory record Official record
Conditions
Intraocular Inflammation, Suspected Endophthalmitis
Interventions
Non Applicable
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 4 Interventional

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

NCT04708145
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Aflibercept Injection
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Beverly Hills, California • Orlando, Florida • Winter Haven, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

NCT01871376
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
Intravitreal aflibercept injection 2.0mg
Drug
Lead sponsor
Gregg T. Kokame, MD
Other
Eligibility
25 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
‘Aiea, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT04592419
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
81
States / cities
Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Not applicable Interventional

30g vs 33g Needle for Intravitreal Injections

NCT03038048
View directory record Official record
Conditions
Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Varying needle size with intravitreal ranibizumab or aflibercept
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 2 Interventional Results available

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00450255
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
ziv-aflibercept, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 9, 2026, 12:42 AM EDT
Terminated Phase 1 Interventional

Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

NCT03396861
View directory record Official record
Conditions
Irvine-Gass Syndrome
Interventions
Aflibercept
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 9, 2026, 12:42 AM EDT
Not listed Phase 1Phase 2 Interventional

Intense Treatment Regimen With Intravitreal Aflibercept Injection

NCT03594461
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept Injection
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 9, 2026, 12:42 AM EDT
Withdrawn Not applicable Interventional

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

NCT02457026
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Aflibercept, Triamcinolone Acetonide, Verteporfin
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 9, 2026, 12:42 AM EDT
Terminated Phase 3 Interventional Results available

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

NCT04757636
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 2.0 aflibercept, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
60
States / cities
Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 2 Interventional

Anti-VEGF Therapy for Acute Thyroid Eye Disease

NCT04311606
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 9, 2026, 12:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

NCT04480463
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
SCD411, Aflibercept
Drug
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Campbell, California • Clearwater, Florida • Coral Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 9, 2026, 12:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

NCT03712904
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Stereotactic Body Radiation Therapy, Ziv-Aflibercept
Radiation · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 9, 2026, 12:42 AM EDT